INTRODUCTION

LARINJECT 50MG contains Ferric carboxymaltose which belongs to the group of medicines called anti-anemic agents. It is an iron replacement medicine used in the treatment of iron deficiency anemia among adult patients who have intolerance or unsatisfactory response to oral iron or in adult patients who have non-dialysis dependent chronic kidney disease. Iron deficiency anemia is a condition in which the body lacks enough amount iron which is responsible for the formation of healthy red blood cells and oxygen transport in the body.

Ferric carboxymaltose contains iron (III) hydroxide complexed with a carbohydrate polymer called carboxymaltose, which is capable of releasing iron. The iron released from the complex helps in the synthesis of hemoglobin and red blood cells, leading to correction of iron-deficiency anemia. LARINJECT 50MG should be given only when your doctor decides that your body needs iron very quickly to build up your iron stores.

The most common side effects of this medicine are injection site irritation, headache, dizziness, high blood pressure and nausea. Before taking this medicine, inform your doctor if you have hypophosphatemia, infection, allergic reactions or liver disease. It is highly contraindicated in patients having an iron-independent anemia or iron overload disorders. It is not recommended for use in children aged under 14 years. It should be used with caution in pregnant or breastfeeding women. Contact your doctor before taking.

USES OF LARINJECT 50MG

• Treats iron deficiency anemia in adult patients

HOW LARINJECT 50MG WORKS

Iron is an important mineral ion responsible for the formation of new red blood cells and hemoglobin and transport of oxygen in the body. Lack of iron may lead to iron deficiency and impairment in the synthesis of red blood cells and hemoglobin and transport of oxygen in the body.

Systemic administration of ferric carboxymaltose effectively replenishes and restores iron in the body. It enhances the formation of hemoglobin and red blood cells and increases the supply of oxygen to the body, leading to correction of iron-deficiency anemia.

DIRECTIONS FOR USE

LARINJECT 50MG will be given to you only by a doctor or nurse into the vein (intravenously) either as an injection or infusion. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and health condition. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.

SIDE EFFECTS OF LARINJECT 50MG

HOW TO MANAGE SIDE EFFECTS

Nausea:

Try taking this medicine with, or just after meals. Stick to simple meals. Do not eat rich or spicy food.

Flatulence:

Eat smaller and frequent meals. Eat and drink slowly, and exercise regularly. If the symptoms get worse, contact your doctor straight away.

Headache:  

Rest and drink plenty of fluids. Do not drink too much alcohol.

Dizziness:

Try to rest and relax. Get enough sleep. Avoid traveling, driving or operating any tools or machines while you are feeling dizzy. If the symptom still persists, contact your doctor for advice.

WARNING & PRECAUTIONS

INTERACTIONS

Talk to your doctor, if you are taking,

• oral iron preparations (e.g. ferrous ascorbate, ferrous sulphate, ferric citrate)

SYNOPSIS

MORE INFORMATION

Store below 20-25°C and keep out of reach of children.

FAQs ABOUT LARINJECT 50MG

What are the symptoms of overdosage of LARINJECT 50MG?

It will be given to you only by a doctor or nurse. So, it is unlikely to receive an overdose. However, repeated administration of this medicine may cause tiredness, stomach pain and joint pain due to increased accumulation of iron in the body.

How much time will LARINJECT 50MG take to work?

It acts within 15 minutes of its administration and its effects lasts for about 7 hours.

Can I take oral iron medicines simultaneously with LARINJECT 50MG?

No. Avoid concomitant use of this medicine with oral iron preparations to avoid the risk of overdosage.

REFERENCES

1. KD. Tripathi. Haematinics and Erythropoietin. Essentials of medical pharmacology. Seventh edition. 2013. Page – 605-606.

2. Kenneth Kaushansky and Thomas J. Kipps. Hematopoietic Agents: Growth factor, Minerals and Vitamins. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1083-1085.

3. American Regent, Inc. Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on February 2018] [Accessed 21st December 2020] https://clinicaltrials.gov/ct2/show/NCT00703937

4. Amreen Naqash, Rifat Ara, Ghulam N Bader. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials. NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. January 2018. [Accessed 21st December 2020] https://pubmed.ncbi.nlm.nih.gov/29304848/

5. Vifor France. Electronic Medicines Compendium (EMC); [Revised on October 2020] [Accessed 21st December 2020] https://www.medicines.org.uk/emc/files/pil.5910.pdf

6. Vifor (International) Inc, Switzerland. U.S. Food & Drug Administration. [Revised on January 2018] [Accessed 21st December 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203565s005lbl.pdf

USEFUL DIAGNOSTIC TESTS

• Serum Ferritin levels
• Serum iron levels
• Total Iron Binding Capacity
• Transferrin Saturation